A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Recruiting

Phase 3

Elacestrant vs. Standard Endocrine TherapyA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Sponsor:

Stemline Therapeutics, Inc.

Code:

NCT06492616

Conditions

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elacestrant

Anastrozole

Letrozole

Exemestane

Tamoxifen

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by Stemline Therapeutics, Inc. on 2025-08-07.